C
Charles R. M. Hay
Researcher at University of Manchester
Publications - 114
Citations - 6679
Charles R. M. Hay is an academic researcher from University of Manchester. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 35, co-authored 111 publications receiving 6106 citations. Previous affiliations of Charles R. M. Hay include Central Manchester University Hospitals NHS Foundation Trust & University of Liverpool.
Papers
More filters
Journal ArticleDOI
Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.
Peter William Collins,Sybil Hirsch,Trevor Baglin,Gerard Dolan,John Hanley,Michael Makris,David Keeling,Ri Liesner,Simon A. Brown,Charles R. M. Hay +9 more
TL;DR: An observational study to identify and characterize the presenting features and outcome of all patients with acquired hemophilia A in the United Kingdom allowed a consecutive cohort of patients, unbiased by referral or reporting practice, to be studied.
Journal ArticleDOI
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.
Sarah C. Darby,Sau Wan Kan,R. J. D. Spooner,Paul L. F. Giangrande,Frank Hill,Charles R. M. Hay,Christine A. Lee,Christopher A. Ludlam,Michael Williams +8 more
TL;DR: Mortality from bleeding and its consequences, and from liver diseases and Hodgkin disease, was increased, but for ischemic heart disease it was lower, and for 14 other specific causes it did not differ significantly from general population rates.
Journal ArticleDOI
The principal results of the International Immune Tolerance Study: a randomized dose comparison.
TL;DR: The International Immune Tolerance Study was a multicenter, prospective, randomized comparison of high-dose and low-dose factor VIII regimens in 115 "good-risk," severe high-titer inhibitor hemophilia A subjects, contributing valuable data toward evidence-based ITI practice.
Journal ArticleDOI
The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.
TL;DR: In this article, the authors used Recombinant Factor VIIa (RVIIIa) as first-line therapy for 14 bleeding episodes and as salvage-therapy for 60 episodes which failed to respond to blood-product therapy given for a median of four days (range 1-21 days).
Journal ArticleDOI
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation
TL;DR: The revised UKHCDO factor (F) VIII/IX Inhibitor Guidelines (2000) are presented and a schema is proposed for inhibitor surveillance, which varies according to the severity of the haemophilia and the treatment type and regimen used.